Introduction
Chemoprevention with natural or synthetic chemical compounds has emerged as an attractive strategy to prevent carcinogenic progression to invasive cancer. Epidemiological studies have provided evidence that high consumption of fruits and vegetables effectively decreases the risk for cardiovascular disease and cancer by improving the antioxidant capacity (1) , suggesting that over two-thirds of cancers might be prevented through lifestyle modification (2) .
Dietary and supplemental sources of vitamin E compounds have been demonstrated to possess unique biological properties (3) that can influence critical pathways involved in cancer (4, 5) , cardiovascular (6, 7) and neurodegenerative disease (8) . Vitamin E occurs naturally in eight isoforms of α-, β-, γ-and δ-tocopherols or tocotrienols (T3). T3, although found in low amounts in human diet, are most abundant in palm, rice and annatto. Rice contains about 50% tocopherol and 50% T3, whereas palm contains ~75% T3 and 25% tocopherol. Annatto ranks highest in T3 content (100%) and it is virtually tocopherol free.
Recent studies have identified T3 as the more effective vitamin E compounds in providing anticancer protection in comparison with the well-established tocopherols (9, 10) . Between health-promoting properties of T3, several lines of evidence support a beneficial effect associated with the prevention of tumor development. One of the studies investigating their role in neoplastic disorders reported that α-and γ-isoform effectively suppressed the development of sarcoma 180, Ehrlich carcinoma and invasive mammary carcinoma (11) . To date, T3 have demonstrated antiproliferative activities against various cancerous cells and activation of apoptosis (12, 13) . We recently evaluated the effect of γ-and δ-T3 on tumor cell growth and apoptosis of human breast cancer cells. In particular, we demonstrated the efficacy of T3 in reducing the viability of human breast cancer cells through a mechanism involving both apoptotic and senescence pathways (14) . However, little is known about the in vivo anticancer effects of these natural compounds of vitamin E. So far, oral administration of T3 mixture (38% γ-T3, 22% α-T3 and 12% δ-T3) in drinking water significantly suppressed spontaneous liver and lung carcinogenesis in C3H/HeN male mice (15) . Furthermore, γ-T3 feeding has been reported to decrease tumor weight and to prolong the survival rate of C57BL female mice transplanted with melanoma (16) . On the other hand, most data on the in vivo effect of T3 have been drawn from studies performed in young mice or rats transplanted with parental tumors or treated with carcinogens as reviewed by Viola et al. (17) ; although informative, these data may not be entirely relevant to the development of most cancers in humans, where the tumor in spontaneous and initiated by clonal expansion from a single cell in vivo.
Therefore, the aim of this study was to investigate the effect of dietary supplementation with T3 extracts from annatto seeds, a 10% γ-and 90% δ-T3 mixture, on the development of mammary tumors appearing spontaneously in HER-2/neu transgenic mice at early age. Underlying mechanisms of the antitumoral action were explored studying the effects of annatto-T3 on apoptosis and senescence molecular markers (p53, p21, p16 and p27), oxidative stress, HER-2/neu expression and activation, induction of senescent-like growth arrest or apoptosis in tumor cells and immunological changes.
Materials and methods

Cell culture and chemicals
Human breast adenocarcinoma SKBR3 cell line was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 μg/ ml streptomycin and 100 U/ml penicillin (all from Invitrogen, Milan, Italy). TUBO breast cancer cell line was established in vitro from a carcinoma that spontaneously arose in BALB/c mice carrying the rat HER-2/neu proto-oncogene driven by the mouse mammary tumor virus (MMTV) promoter. TUBO cells were maintained in Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum. The mouse T-lymphoma cells YAC-1, used in natural killer cytotoxic assay, were grown in suspension in RPMI 1640 medium supplemented with 10% fetal bovine serum.
Annatto-T3 oil containing 90% δ-T3 and 10% γ-T3 was obtained from DeltaGold® product (American River Nutrition, Hadley, MA). Highperformance liquid chromatography (HPLC)-purified δ-T3 was purchased from Sigma-Aldrich (Milan, Italy). In in vitro experiments, breast cancer cells were treated with annatto-T3 oil dissolved in ethanol at doses ranging from 0.5 to 500 μM for the times indicated.
Animals FVB/N HER-2/neu transgenic female mice for the activated rat neu oncogene were obtained from Charles River (Hollister, CA) and maintained under specific pathogen-free conditions under a standard 12 h light/12 h dark regimen in our animal facilities. Mice were housed in plastic non-galvanized cages and fed with standard pellet food (Nossan, Italy) and tap water ad libitum. The study was conducted in accordance with the ethical standards and according to national and international guidelines and has been approved by the animal research ethics committee of the INRCA-IRCCS.
Abbreviations: HPLC, high-performance liquid chromatography; MMTV, mouse mammary tumor virus; ROS, reactive oxygen species; T3, tocotrienol.
Annatto-tocotrienols in HER-2/neu transgenic mice
Experimental design
Female FVB/N mice were analyzed in three different experiments. In each experiment, 4-month-old mice were randomly divided into three groups (n = 10 for each group), which received the following doses by oral gavage for three times a week: (i) 50 mg/kg annatto-T3 in olive oil, (ii) 100 mg/kg annatto-T3 in olive oil and (iii) olive oil vehicle alone (control group). Olive oil was chosen as vehicle due to its low content of vitamin E (i.e. 51 p.p.m.) (18) . Once a week, all mice were palpated for the detection of mammary tumors. The neoplastic masses were measured with caliper in the two perpendicular diameters. Progressively growing masses of >3 mm in mean diameter were regarded as tumors. Tumor volume was assessed with the following formula: (length × width 2 )/2. Tumor multiplicity was calculated as mean number of palpable mammary carcinomas per mouse. In each group of mice, the number of lung metastases present at the end of the treatment was evaluated after staining by endotracheal infiltration with 15% china ink solution. Lungs were fixed and bleached in Fekete's solution (300 ml 70% ethanol, 30 ml 37% formaldehyde and 5 ml glacial acetic acid) (19) . The number of macroscopic pulmonary tumor nodules was counted in each of the five lobes. Diameter of metastatic lesions were measured with calipers and volumes were calculated by 4/3πr 3 , assuming the metastases were spherical (19) . All assays were performed in tumor masses of 4-5 mm of diameter.
Immunophenotyping
Whole spleens were dissociated into single-cell suspensions of splenocytes using the gentleMACS Dissociator (Miltenyi Biotec, Germany). Splenocytes suspension was filtered and then stratified on Lympholyte-M (Cederlane Laboratories, Canada). After density gradient centrifugation, viable lymphocytes were washed twice with phosphate-buffered saline, counted and suspended in RPMI 1640 with 10% fetal bovine serum. The phenotype of spleen cells was analyzed using the following panel of fluorescein isothiocyanate and phycoerythrin-labeled monoclonal antibodies: anti-CD4, anti-CD8, antiCD49b (all from Miltenyi Biotec), anti-TCRγδ, anti-CD3, anti-CD25 and anti-FOXP3 (all from eBioscience, San Diego, CA). Stained cells were analyzed by a flow cytometer Epics XL (Coulter, Miami, FL).
Natural killer assay
The cytotoxic assay was performed using a fluorimetric method as reported previously (20) . YAC-1 tumor cells were labeled with carboxyfluorescein diacetate and incubated with effectors spleen cells. Effectors:target cell ratios from 200:1 to 25:1 were tested in triplicate. The percentage of specific lysis was calculated as follows: % specific lysis = [(F med − F exp )/F med ] × 100, where F represents the fluorescence of the solubilized cells after the supernatant has been removed, F med is the F from target incubated in medium alone and F exp is the F from target incubated with effector cells. Lytic units (LU 20 /10 7 cells) were calculated by using a computational method (21) . One lytic unit corresponds to the number of effector cells required to produce 20% specific lysis.
Cell viability analysis SKBR3 and TUBO cell lines were plated in 96-well culture plates at a density of 10 4 cells/well in 100 μl of complete medium. They were allowed to adhere for 24 h, after which a medium containing the experimental agent was added. The plates were incubated for periods of time indicated and then AlamarBlue solution (Biosource, Invitrogen) was added to each well at a concentration of 10% (v/v). After 2 h incubation at 37°C, the fluorescence was measured at 530 nm excitation wavelength and 590 nm emission wavelength in a plate reader (Wallach, Turku, Finland).
Quantification of apoptosis by flow cytometry
Apoptosis was measured through subdiploid DNA peak analysis after staining with propidium iodide (22) . The propidium iodide fluorescence of individual nuclei was determined using an Epics XL flow cytometer (Coulter, Hialeah, FL) and the percentage of apoptotic nuclei was determined on the basis of the number of subdiploid DNA peak in the DNA fluorescence histogram.
Reverse transcription-polymerase chain reaction, PCR and quantitative real-time mRNA analysis
Total RNA was isolated from 10 6 cells or tumor tissues using RNeasy kit (Qiagen, Milano, Italy) according to the manufacturer's instructions. Reverse transcription-polymerase chain reaction and PCR for perforin, granzyme B and β-actin were performed as described previously (23) . Relative quantification of mRNA expression was achieved by quantitative real-time PCR using fluorescent dye SYBR green (BioRad, Richmond, CA) during PCR amplification (iQ5 Real-time Detection System, Bio-Rad). The human primers used were as follows: GAPDH, 5′-CAACAGCGACACCCACTC-3′ and 5′-AGGCCATGTGGGCCATGA-3′; p53, 5′-GCGCACAGAGGAAGAGAATC-3′ and 5′-CTCTCGGAACA-TCTCGAAGC-3′; p21, 5′-GGAAGACCATGTGGACCTGT-3′ and 5′-GGCG-TTTGGAGTGGTAGAAA-3′; p16, 5′-GAGCAGCATGGAGCCTTC-3′ and 5′-CATCATCATGACCTGGATCG-3′; p27, 5′-CCGGCTAACTCTGA GGA-CAC-3′ and 5′-CATTTGGGGAACCGTCTAAA-3′. Each set of primers was also designed across intron/exon boundaries to detect genomic DNA contamination. Variation in gene expression in treated cells with respect to the control (untreated cells) was determined using the formula:
∆∆ t , where ΔΔc t = δE − δC, δE = no. of gene − no. of cycles of housekeeping gene (GAPDH) in the treated cells and δC = no. of cycles of DR gene − no. of cycles of housekeeping gene in the control cells.
Western blot analysis
Whole cell extracts and immunoblots were carried out as described previously (14) . Tumor tissue samples were homogenized in the same buffer using the gentleMACS Dissociator (Miltenyi Biotec) according to the manufacturer's instructions. Immunoblotting was performed using antibodies against HER-2/ neu, phospho-HER-2/neu and p21 (Santa Cruz Biotechnology, Santa Cruz, CA). β-Actin antibody (Santa Cruz Biotechnology) was used as a control for protein loading. Proteins were detected with horseradish peroxidase-conjugated mouse or rabbit immunoglobulin G secondary antibody (Calbiochem, Merck KGaA) and then developed with the enhanced chemiluminescence system (GE Healthcare, Chicago, IL). The intensity of individual immunoreactive protein bands was determined by scanning the developed X-ray films and measuring the optical density and area of the bands using GS-800 Calibrated Densitometer (Bio-Rad). Normalization for loading differences was achieved by dividing the densitometry values for individual bands by the densitometry values for β-actin in the same lane.
SA-β-gal staining and image analysis
Senescence-associated SA-β-gal activity was detected and analyzed as described previously (24) .
Detection of in situ cell death
For in situ staining of apoptotic cells, the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method was performed using a kit (Roche, Milan, Italy), according to the manufacturer's instructions. Detection was done with diaminobenzidene substrate (Vector Laboratories, CA). Negative control without terminal transferase was included. Positive control was included, treating tumor cell with 80 U/ml DNase I (Invitrogen) to induce DNA strand breaks. Sections were counterstained with hematoxylin. Quantitative studies of apoptotic cells from control and treated mice were performed by evaluating five randomly chosen fields in each sample. Individual cells were counted under ×250 microscopic field.
HPLC analysis of T3 and tocopherol
In vitro and in vivo uptake were determined using HPLC apparatus (Varian) coupled to an electrochemical detector (EC400) with a glassy carbon working electrode operated in the oxidation mode (0.6 V versus Ag/AgCl). Briefly, cells were treated as required and then harvested. Then cells were resuspended with phosphate-buffered saline and antiproteolytics (Sigma-Aldrich) and placed on ice. An aliquot of 100 µl was used to bicinchoninic acid protein assay. After adding the internal standard tocol, 1 ml of ethanol and 3 ml of n-hexane were added in sequel and the samples were vortex mixed for 3 min after each step. The lipid fraction extracted in the hexane layer was separated by centrifugation and collected. This extraction procedure was repeated twice and the organic layer was unified in a Pyrex tube and dried down under a stream of nitrogen at 45°C. The residue was dissolved in 200 μl of methanol and inject to the HPLC system. The results corrected for the recovery of the internal standard were expressed in microgram per milligram of protein.
Reactive oxygen species generation by flow cytometry
To monitor cellular production of reactive oxygen species (ROS), we utilized a cell-permeable probe, 5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate, that is a non-fluorescent, electronically neutral molecule that is readily taken up by intact cells. Upon oxidation, the 5-(and-6)-carboxy-2′,7′dichlorodihydrofluorescein becomes the fluorescent dye 5-(and-6)-carboxy-2′,7′-dichlorofluorescein. The probe is oxidized to yield high intensity of fluorescence in the presence of simple (hydrogen peroxide) and more complex related peroxides. The 5-(and-6)-carboxy-2′,7′-dichlorofluorescein fluorescence intensity is, therefore, proportional to the amount of ROS formed. Fluorescence was measured by flow cytometry using a band-pass filter centered at 530 nm. As a positive control, cells were treated with 500 µM H 2 O 2 for 4 h.
Mitochondrial inner transmembrane potential
Mitochondrial inner transmembrane potential (ΔΨ) was assessed using the polychromatic 5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidoazolylcarbocyanino iodide (JC-1; Molecular Probes, Invitrogen). JC-1 shows red
fluorescence in energized mitochondria, whereas it is green in mitochondria with dissipated ΔΨ, suggestive of mitochondrial dysfunction. In brief, cells were treated as required, after which they were incubated for 15 min with 1 μg/ ml JC-1 at 37°C. The cells were then harvested, washed with phosphate-buffered saline and analyzed by fluorescence-activated cell sorting. Since appearance of green fluorescence precedes disappearance of red fluorescence, the population of cells with low ΔΨ was evaluated on the basis of cells exhibiting increased green fluorescence.
Statistical analysis
All experiments were performed at least three times. Differences in tumor incidence were evaluated by the Mantel-Haenszel log-rank test; differences in tumor multiplicity were evaluated by analysis of variance and StudentNewman-Keuls post hoc tests; differences in lung metastasization were evaluated by one-way analysis of variance on ranks test followed by Dunn's test and differences in mRNA expression and in immune parameters were evaluated by Student's t-test. Difference between means was considered significant at P ≤ 0.05. Data analysis was performed with SigmaStat software version 1.03 (Jandel Scientific, Germany) and Systat 10 (SPSS) software.
Results
Effect of annatto-T3 supplementation on the kinetics of tumor growth and lung metastasization
We examined the effect of annatto-T3 on spontaneous breast carcinogenesis in HER-2/neu transgenic mice. As shown in Figure 1A , the first mammary tumor appeared in both annatto-T3-treated and untreated mice at 21 weeks of age. The tumor incidence increased progressively with increasing age of mice, affecting 50% of control mice at 22 weeks of age. In mice supplemented with annatto-T3 (100 mg/kg), the kinetics of appearance of mammary tumors was significantly delayed compared with controls (P = 0.004) with 50% of mice bearing tumors at week 27. The kinetics of tumor incidence in 50 mg/kg of annatto-T3-treated mice was not different from that of control animals. As shown in Figure 1B , a statistically significant difference of tumor volume was observed by 26 weeks of age in annatto-T3 (100 mg/kg)-treated mice compared with either control (P = 0.001) or 50 mg/kg of annatto-T3-treated groups (P = 0.02). As shown in Figure 1C , starting from 24 weeks of age, the mean of mammary tumors developing in HER-2/neu mice was significantly reduced in annatto-T3 (100 mg/kg)-supplemented group compared with control and 50 mg/kg groups (P < 0.05). As shown in Table I , no difference was observed on the incidence of metastasis (the mean number of metastasis was 1, 0.5 and 0.44 for control, 50 mg/kg or 100 mg/kg of annatto-T3, respectively), but mice that received either 50 or 100 mg of annatto-T3 showed significant reduction of size of lung metastasis when compared with control animals (P < 0.05, treatments versus control). In selected experiments, we performed a 60 mg/kg supplementation with α-tocopherol acetate. No statistically significant difference between treated and control groups was observed on the kinetics of tumor incidence, on tumor volume and multiplicity (data not shown). Figure 2A shows the δ-T3 levels in normal tissues and tumors in 100 mg/kg annatto-T3 and in control groups. δ-T3 was detected in normal tissues and tumors of mice 1 h after last supplementation. The increase of δ-T3 level in serum was observed in annatto-T3 (100 mg/ kg)-treated mice compared with untreated animals (171.8 ± 179.2 versus 19.4 ± 14.6 nmol/g). δ-T3 was cleared from serum within 24 h returning to control levels (13.1 ± 2.0 versus 14.5 ± 7.3 nmol/g). The same trend was observed in liver, although the difference between the levels at 1 and 24 h was not significant (80.5 ± 19.5 versus 19.1 ± 33.0 nmol/g). δ-T3 levels of <10 nmol/g were found in liver of control group mice. Surprisingly, a large amount of δ-T3 was detected in tumor masses of annatto-T3 (100 mg/kg)-treated mice, without difference between early and late time (347.1 ± 350.3 and 407.0 ± 425.6 nmol/g, respectively). δ-T3 levels of <46 nmol/g were found in tumors of control group. γ-T3 was not found in samples at the times and doses analyzed (data not shown).
Biodistribution of δ-T3 in serum, liver and tumors of mice
Analysis of senescent-like phenotype, in situ apoptosis and HER-2/ neu expression in tumor tissue from annatto-T3-supplemented mice
As shown in Figure 2B , annatto-T3 (100 mg/kg) supplementation increased the number of cells with a senescent-like phenotype in mammary tumor samples, as evidenced by the augmented number of cells with enlarged and flattened morphology and with increased SA-β-gal staining. Image analysis processing showed a significantly increased percentage area of SA-β-gal staining in tumor masses from annatto-T3-treated mice (0.529 ± 0.528) in comparison with control mice (0.158 ± 0.168; P = 0.002).
The presence of apoptosis in tumor samples obtained from untreated or annatto-T3 (100 mg/kg)-supplemented mice was then evaluated in situ using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay. As shown in Figure 2C , a greater number of apoptotic cells were found in tumors from supplemented mice. The mean number of dead tumor cells in mammary gland of annatto-T3-treated Fig. 1 . Effect of annatto-T3 supplementation on survival and tumorigenesis. FVB/N transgenic mice (n = 10 for each group) were supplemented three times a week with 50 or 100 mg/kg of annatto-T3 or vehicle alone and analyzed for the kinetics of tumor incidence (A), tumor volume (B) and tumor multiplicity (C). Difference in tumor incidence was significant between annatto-T3 (100 mg/kg) group versus control group (P = 0.004). Tumor volume was significantly different in 100 mg/kg group versus control (P = 0.001) or 50 mg/kg group (P = 0.02). The mean tumor number was significantly reduced in annatto-T3 (100 mg/kg) group compared with control or 50 mg/kg group (P < 0.05). Data are from one of three experiments. or control mice was 22.2 ± 19.5 or 11.1 ± 9.6, respectively (P < 0.02). No evidence of apoptosis was present in negative control. Strong positivity was obtained in DNase-treated tumor samples (positive control).
We then analyzed the HER-2/neu protein expression and phosphorylation in tumor masses from untreated and annatto-T3 (100 mg/kg)-supplemented mice through western blot assay. As shown in Figure 2D , both expression and phosphorylation were reduced in mammary tumor from annatto-T3-treated mice compared with control mice, although the difference was not statistically significant.
No significant change of all analyzed parameters has been detected in tumor masses from 50 mg/kg-treated mice (data not shown).
Effect of annatto-T3 supplementation on immune parameters
The modulation of immune system determined by annatto-T3 supplementation was evaluated through the analysis of immune phenotype, natural killer cytotoxicity and intratumoral expression of mRNA coding for perforins and granzyme. As shown in Figure 3A Figure 3B , both the number and the cytotoxicity of natural killer cells in the spleen were reduced, even if not significantly, in annatto-T3 (100 mg/ kg)-supplemented mice. Neither granzyme nor perforins were detected in tumor tissue from control or annatto-T3-supplemented mice ( Figure 3C ).
In vitro cytotoxicity of annatto-T3 in SKBR3 tumor cell line
The in vitro antitumor activity of annatto-T3 was first compared with HPLC-purified δ-T3 ( Figure 4A ). The viability of SKBR3 cells was assessed in presence of purified δ-T3 or annatto-T3 in concentrations ranging from 10 to 500 μM for 24 h. As shown in Figure 4A , both compounds tested inhibited the viability of SKBR3 cells in a dose-dependent manner. Annatto-T3 was lightly less effective with respect to purified δ-T3 with IC 50 of 36 ± 14 and 22 ± 7 μM. To evaluate the effect of annatto-T3 on cell proliferation, SKBR3 cells were seeded in culture flasks and cultured for 2 days, then starved overnight and, on day 3, annatto-T3 was added. As shown in Figure 4B , untreated SKBR3 cells continued their progressive growth until day 5 of culture, whereas a time-and dose-dependent inhibition of cell growth was observed in annatto-T3-treated samples. Complete growth suppression was achieved at 25 μM with cell number falling below the plating density (data not shown). To evaluate whether the inhibitory effects of annatto-T3 on SKBR3 cell viability could be due to changes in apoptotic cell death, the cells were exposed for 24 h to increasing concentrations of annatto-T3 and apoptosis was measured by flow cytometry using propidium iodide staining. As shown in Figure 4C , treated SKBR3 underwent apoptosis in a dose-dependent manner, with increasing number of apoptotic cells starting from 25 μM dose and picking at 50 and 100 μM of annatto-T3 or purified δ-T3 (P at least <0.05 versus control).
Effect of in vitro annatto-T3 on murine TUBO cell line
To establish whether the effect of in vivo supplementation with annatto-T3 was related to a direct action on tumor tissues, we analyzed the uptake, viability and intracellular ROS production in HER-2/neu + TUBO cells. As shown in Figure 5A , annatto-T3, at concentrations ranging from 0.5 to 100 μM, inhibited the viability of TUBO cells in a dose-and time-dependent manner. Then, the level of δ-T3 in cancer cells was determined by HPLC after treatment with 50 μM of annatto-T3 for 15 h. As shown in Figure 5B , a large amount of δ-T3 was internalized after 15 h of incubation in TUBO cells (2.5 μg δ-T3/mg of protein extract). The levels of δ-T3 in untreated cells were undetectable.
We then investigated the generation of ROS in TUBO cells in presence of 50 μM annatto-T3. The indirect flow cytometric assay, using the probe 5-(and-6)-carboxy-2′,7′-dichlorofluorescein, indicated a time-dependent ROS accumulation in treated cells (P < 0.05 versus the respective control, Figure 5C ). At the same conditions, the destabilization of mitochondria was evaluated. Figure 5D shows that the treatment of TUBO cells with 50 μM annatto-T3 results in an increasing number of cells with low ΔΨ occurring in 12.7% at 4 h of treatment, 77.2% within 28 h and 76.8% at 44 h of treatment (P < 0.05 versus the respective control).
Effect of in vitro annatto-T3 on the modulation of cell-cycle checkpoint regulators in SKBR3 tumor cells
To establish whether the effect of annatto-T3 on senescent-like growth arrest observed on tumor masses of treated mice could be related to a modulation of molecular cell-cycle checkpoint regulators, we measured p53, p21 WAF1 , p16
INK4a and p27 kip1 expression in untreated and annatto-T3-treated SKBR3 cells. As shown in Figure 6A , annatto-T3 induced a significant dose-dependent upregulation of p53, p21 and p27 mRNA, as defined by a change in the extent of expression at the reverse transcription-polymerase chain reaction analysis. Although low annatto-T3 doses were sufficient to significantly increase the levels of p53 and p27 over the control, only higher dose (50 μM annatto-T3) was able to increase transcription of p21 mRNA. The increase of p21 protein has been confirmed by western blot analysis as shown in Figure 6C . No significant modulation in p16 expression was observed in analyzed samples.
Effect of in vitro annatto-T3 treatment on HER-2/neu expression and phosphorylation
As shown in Figure 6B , the HER-2/neu mRNA expression was significantly reduced in SKBR3 cells after treatment with 25, 50 or 100 μM of annatto-T3 (0.56 ± 0.05, 0.59 ± 0.06 and 0.55 ± 0.08, respectively, P < 0.05 versus control). The HER-2/neu translation product was measured by western blot analysis at the same conditions of treatment. Twenty-four hours incubation of SKBR3 with 25 and 50 μM annatto-T3 reduced the p185 protein with respect to control untreated cells ( Figure 6C ). This reduction in HER-2/neu expression was associated with a dose-dependent suppression of HER-2/neu tyrosine phosphorylation, when compared with control cells (see Figure 6C and quantification in the right panel).
Discussion
In this paper, we demonstrate for the first time the anticancer activity of annatto-T3 supplementation in a spontaneous breast tumor model. The data show that (i) annatto-T3 supplementation delays the development of spontaneous mammary tumors and reduces the number and volume of tumor masses and the size of lung metastases in HER-2/neu transgenic mice; (ii) annatto-T3 supplementation induces senescent-like growth arrest and apoptosis in tumoral mammary glands; (iii) in vitro annatto-T3 induces apoptosis, senescent-like growth arrest and ROS in human and murine breast cancer cell lines; (iv) both in vivo and in vitro annatto-T3 down regulates HER-2/neu gene expression and phosphorylation.
HER-2/neu transgenic mice spontaneously develop tumors in their mammary glands at an early age (25, 26) . We show that oral administration with 100 mg/kg annatto-T3 before the appearance of palpable mammary tumors determines a significant slowing down of the kinetic of tumor development, a lower number and volume of tumor masses, and a lower size of lung metastasis.
Our data on the anticancer effect of annatto-T3 in HER-2/neu transgenic mice represent the first study conducted in a spontaneous breast tumor model that emulate human disease. Moreover, our data extend previous studies conducted with different T3 formulations in animal models transplanted with parental tumors or treated with carcinogens. In these studies, T3-enriched mixtures from palm oil, but not tocopherols preparation, were effective in preventing dimethylbenzanthracene-induced mammary carcinogenesis in rats (27, 28) . Nesaretnam et al. (29) also observed a significant delay in the onset, incidence and size of tumor growth resulting from inoculation of MCF-7 breast cancer cells in nude mice supplemented with TRF compared with the controls.
The anticancer effect of annatto-T3 was accompanied by the high δ-T3 accumulation in tumors (Figure 2A ). Our data agree and expand a previous study in which high accumulation of δ-T3 in hepatocellular carcinoma HepG2 cells after in vitro δ-T3 treatment was shown to cause the death of cancer cells (15) . Moreover, another study showed the accumulation of δ-T3 in pancreatic tumors after oral administration of 100 mg/kg of δ-T3 in athymic nude mice, without toxicity or side effects (30) . Altogether, these findings suggest that tumor tissue is a good target for accumulation of δ-T3 and that these vitamin E isomers may reach concentrations able to block tumor growth in cancer cells.
The effectiveness of annatto-T3 treatment in reducing the size of lung metastases was already present at the lower dosage (50 mg/kg) compared with control mice (Table I ). This antimetastatic effect did not significantly increase after administration of 100 mg/kg annatto-T3, revealing the lack of a dose-response relation and suggesting the possibility that the progress of metastasization may be delayed by lower annatto-T3 doses than those required to inhibit growth of primary mammary tumors. Such phenomenon could be explained through a different accumulation of bioactive vitamers in metastatic target tissues, as well as a different degree of angiogenesis and vascularization.
The effectiveness of T3 as anticancer agents has been reported previously to be related to their cytoprotective activity, to antiproliferative effects on cancer cells and to the induction of tumor cell apoptosis (12, 13, 17) . In this study, we extend the actual knowledge on the mechanism of action of T3 providing further potential mechanisms involved in their anticancer effect. According to recent in vitro evidence on purified T3 (14) , annatto-T3 supplementation was able to induce apoptosis and senescent-like terminal proliferation arrest both in vivo and in vitro. It has been suggested that senescent-like growth arrest may be a significant determinant of tumor response to anticancer agents in conditions in which the induction of cell death does not explain by itself the antiproliferative effect (31, 32) . Our data demonstrate that annatto-T3 induces senescent-like growth arrest both in vivo and in vitro. In fact, an increased number of cells positive for SA-β-gal was found in mammary tumors from annatto-T3-treated mice. Furthermore, in vitro annatto-T3 was able to slow down the kinetics of growth, to increase the number of SA-β-gal positive cells and to induce a dose-dependent upregulation of p53, p21 and p27 mRNA. Both apoptosis and senescent-like growth arrest were associated with a downregulation of HER-2/neu expression and phosphorylation in tumors from annatto-T3-supplemented mice and in tumor cell cultures. The relationship between reduced expression and activation of HER-2/neu oncogene and induction of apoptosis was reported previously by us (24) and others (33) in other experimental models. Since in transgenic mice the overexpression of HER-2/neu is under the control of the MMTV promoter, we wanted to rule out the possibility that the annatto-T3 effect on HER-2/neu was due to a modulation of MMTV promoter. The data reported in Figures 4 and   6 , which have demonstrated that annatto-T3 in vitro modulates the apoptosis, the senescence markers and the HER-2/neu expression in SKBR3 tumor cells (in which HER-2/neu is not under the control of MMTV), confirmed that annatto-T3 does not affect the MMTV promoter.
Although vitamin E (both tocopherols and T3) is known as a potent antioxidant, the antitumor activity of vitamin E may not be associated with its antioxidant activity. Rather, we have found an increased oxidative stress in tumor cells treated with annatto-T3. The annatto-T3-dependent increased ROS may be involved in the activation of both apoptosis and senescent-like growth arrest in tumor cells. Our results agree with the pro-oxidant effect of analogs of vitamin E, which was recently described to occur in neutrophils as well as in isolated low-density lipoprotein (34, 35) .
In conclusion, this study demonstrates that annatto-T3 may exert important anticancer effects delaying the development and the metastasizing capacity of tumors in mice transgenic for the HER-2/ neu oncogene. The antitumor effect of annatto-T3 might be related to the induction of oxidative stress, senescent-like growth arrest and INK4a and p27 kip1 and p185 HER-2/neu after annatto-T3 treatments in SKBR3 cells. Cells were exposed to increasing concentrations of annatto-T3 for 24 h and harvested for mRNA and protein extraction. Results are representative of at least two independent experiments (A) and (B); relative change in mRNA expression was assessed by real-time PCR. mRNA levels are expressed as fold induction versus untreated cells. GAPDH was used as control. (C) Western blot analysis using HER-2/neu, phospho-HER-2/neu, p21 and β-actin antibodies. Graphs on the right panel represent quantification of the blots by the GS-670 imaging densitometer after normalization with respect to β-actin. All data are expressed as the mean ± SD of three independent experiments. # P < 0.05. 
